DE69940971D1 - Verwendung von erythropoietin zur behandlung von primärer hämochromatosen - Google Patents

Verwendung von erythropoietin zur behandlung von primärer hämochromatosen

Info

Publication number
DE69940971D1
DE69940971D1 DE69940971T DE69940971T DE69940971D1 DE 69940971 D1 DE69940971 D1 DE 69940971D1 DE 69940971 T DE69940971 T DE 69940971T DE 69940971 T DE69940971 T DE 69940971T DE 69940971 D1 DE69940971 D1 DE 69940971D1
Authority
DE
Germany
Prior art keywords
hemo
chromates
erythropoietin
primary
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940971T
Other languages
English (en)
Inventor
Rene Gottschalk
Paul Lehmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998116035 external-priority patent/DE19816035A1/de
Priority claimed from EP98250222A external-priority patent/EP0965349A1/de
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Application granted granted Critical
Publication of DE69940971D1 publication Critical patent/DE69940971D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69940971T 1998-04-09 1999-04-09 Verwendung von erythropoietin zur behandlung von primärer hämochromatosen Expired - Lifetime DE69940971D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1998116035 DE19816035A1 (de) 1998-04-09 1998-04-09 Verwendung von Erythropoietin zur Behandlung von Hämochromatosen
EP98250222A EP0965349A1 (de) 1998-06-18 1998-06-18 Verwendung von Erythropoietin zur Behandlung von Hämochromatosen
PCT/EP1999/002422 WO1999052542A1 (en) 1998-04-09 1999-04-09 Use of erythropoietin for the treatment of haemochromatoses

Publications (1)

Publication Number Publication Date
DE69940971D1 true DE69940971D1 (de) 2009-07-23

Family

ID=26045400

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940971T Expired - Lifetime DE69940971D1 (de) 1998-04-09 1999-04-09 Verwendung von erythropoietin zur behandlung von primärer hämochromatosen

Country Status (10)

Country Link
US (1) US6676947B1 (de)
EP (1) EP1085900B1 (de)
JP (1) JP3930250B2 (de)
AR (1) AR019025A1 (de)
AT (1) ATE433323T1 (de)
AU (1) AU3814599A (de)
DE (1) DE69940971D1 (de)
DK (1) DK1085900T3 (de)
ES (1) ES2326501T3 (de)
WO (1) WO1999052542A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004063927A1 (de) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
WO2009100255A2 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
KR100701422B1 (ko) * 2004-07-29 2007-03-30 주식회사 하이닉스반도체 케미컬 어택을 방지할 수 있는 반도체소자 및 그 제조 방법
WO2006089228A2 (en) 2005-02-16 2006-08-24 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
JP5680534B2 (ja) 2008-07-23 2015-03-04 イーライ リリー アンド カンパニー 修飾されているウシｇ−ｃｓｆポリペプチドおよびそれらの使用
PE20110832A1 (es) 2008-09-26 2011-11-24 Ambrx Inc Polipeptidos de eritropoyetina felina modificados
EP2316334A1 (de) 2009-10-22 2011-05-04 Fresenius Medical Care Deutschland GmbH Verfahren zur Beurteilung des Flüssigkeitszustands und/oder der Empfindlichkeit für eine Flüssigkeitsentfernung eines Patienten, Steuerung und Vorrichtungen
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
US5013718A (en) 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
DE3729863A1 (de) 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
AU723740B2 (en) * 1995-06-06 2000-09-07 Howmedica Inc. Biocompatible hydroxyapatite formulations and uses therefor
TW586933B (en) * 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
FI964138A (fi) 1996-10-15 1998-04-16 Nokia Telecommunications Oy Kanavanvarausmenetelmä ja radiojärjestelmä

Also Published As

Publication number Publication date
WO1999052542A1 (en) 1999-10-21
AR019025A1 (es) 2001-12-26
DK1085900T3 (da) 2009-08-10
ATE433323T1 (de) 2009-06-15
JP2002511418A (ja) 2002-04-16
ES2326501T3 (es) 2009-10-13
EP1085900A1 (de) 2001-03-28
AU3814599A (en) 1999-11-01
JP3930250B2 (ja) 2007-06-13
US6676947B1 (en) 2004-01-13
EP1085900B1 (de) 2009-06-10

Similar Documents

Publication Publication Date Title
DE69821667D1 (de) Kardioverter zur Behandlung von Vorhofflattern
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE218355T1 (de) Verwendung von mycobacterium zur tumorbehandlung
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE69940971D1 (de) Verwendung von erythropoietin zur behandlung von primärer hämochromatosen
DE69939723D1 (de) Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE69918541D1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons
DE69936449D1 (de) Verfahren zur herstellung von 1,3-disubstituierten-4-oxocyclischen harnstoffen
DE69408394D1 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
DE59104437D1 (de) Verwendung von molybdänverbindungen zur lack-koagulierung.
DE60021521D1 (de) Isonipecotamide zur behandlung von integrin vermittelten störungen
DE50011084D1 (de) Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
ATE235494T1 (de) Imino-aza-anthracyclonderivate zur behandlung von amyloidosis
DE69920003D1 (de) Verfahren zur herstellung von 1,3-disubstituierten-4-oxocyclischen harnstoffen
ATE226440T1 (de) Zusammensetzung zur behandlung von psoriasis
DE69934336D1 (de) Verwendung von halofuginone zur behandlung von urethralstriktur
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien

Legal Events

Date Code Title Description
8364 No opposition during term of opposition